High levels of these populations in the serological and/or cellular responders were validated using flow cytometry-based analysis of the CD4+ cytotoxic T-cell fraction, defined by co-expression of CD3, CD4, perforin, and/or granzyme (Fig. S2B), in an independent set of PBMCs derived from patients with MM after the 3rd vaccination (Fig. 2F). The gene discussed is CD4; the disease is Miyoshi myopathy.